Highlights

  • EMVision is preparing to add an acute ischaemia detection endpoint to its Pivotal (Validation) Trial.
  • The trial underpins the planned FDA De Novo clearance pathway for the emu™ Brain Scanner.
  • Pivotal Trial recruitment has surpassed 125 patients across US and Australian sites.
  • Full enrolment is anticipated from late CY2026 / early CY2027.  
  • No device-related adverse events have been reported to date in the Pivotal Trial.
  • EMVision estimates the expanded trial strategy could save up to two years and multi-million dollars versus a standalone ischaemia trial.
  • Cash reserves stood at A$18.4 million as at 31 March 2026.
  • A further A$6.2 million in non-dilutive grant funding remains available.

EMVision Medical Devices Limited (ASX:EMV) has provided an update on its clinical development program, outlining plans to expand the Pivotal (Validation) Trial for its emu™ point-of-care Brain Scanner to include an acute ischaemia detection endpoint alongside the existing haemorrhage detection objective.

The Pivotal (Validation) Trial is the key study supporting the planned FDA De Novo clearance pathway for the emu™ device, which is designed to assist with earlier stroke triage and treatment decisions directly at the bedside. EMVision stated that modifications to the trial are expected to be incremental rather than substantial, largely because ischaemic stroke patients are already being enrolled within the existing study framework.

Under the proposed expansion, the Company intends to engage with the FDA through a pre-submission Q-Sub meeting to align on the additional endpoint, associated clinical claims and required performance thresholds. EMVision believes embedding ischaemia validation into the current Pivotal Trial could potentially save up to two years and multi-million dollars in future trial costs compared with undertaking a standalone validation study later.

Recruitment in the Pivotal (Validation) Trial has now surpassed 125 patients across eight active sites in the United States and Australia, while the parallel Continuous Innovation Study has enrolled more than 100 patients. The Company expects full enrolment in the Pivotal Trial from late CY2026 or early CY2027, followed by sequential cohort read-outs.

What Was Announced

The primary development in the update is EMVision’s decision to actively prepare for the addition of an acute ischaemia detection endpoint to the ongoing Pivotal (Validation) Trial for the emu™ Brain Scanner.

The trial’s existing primary objective is to demonstrate haemorrhage detection sensitivity and specificity above 80% to support FDA regulatory submission. By adding ischaemia detection into the same trial infrastructure, EMVision aims to validate a broader clinical use case within the same regulatory pathway.

Because the current trial already enrols suspected stroke patients, including ischaemic stroke presentations, the Company expects only modest protocol modifications will be required. These changes are expected to involve adjustments to sample sizing for the ischaemic sub-cohort and formal specification of the additional endpoint analysis through a protocol amendment.

The Company confirmed that it intends to engage the FDA through a Q-Sub meeting to ensure alignment around the proposed endpoint expansion and associated statistical objectives.

The Pivotal Trial currently operates across six US sites — including Mayo Clinic Florida, Mt Sinai Hospital New York, Mt Sinai West, Ronald Reagan UCLA Medical Center and Memorial Hermann facilities in Texas — alongside Australian sites including Royal Melbourne Hospital and Liverpool Hospital. Princess Alexandra Hospital is also transitioning into the Pivotal Trial program.

EMVision stated that the emu™ device continues to integrate into hospital code stroke workflows without disruption and that no device-related adverse events have been reported to date.

Clinical Program Progress

Beyond the endpoint expansion plans, the update also highlighted broader momentum across EMVision’s clinical development activities.

The Pivotal (Validation) Trial has now surpassed 125 enrolled patients across Training and primary analysis cohorts, with the study targeting a total of 300 suspected stroke participants for the primary analysis cohort. This includes 150 intracranial haemorrhage patients and 150 “other” participants.

The trial design has been structured to support sequential validation of additional diagnostic features over time without requiring separate full validation studies for each new indication. This flexibility has enabled the Company to pursue ischaemia validation within the current regulatory framework.

In parallel, the Continuous Innovation Study has enrolled more than 100 patients. The study functions as a real-world data and algorithm development platform, supporting refinement of detection features and broader device capability expansion. John Hunter Hospital remains active within the study, while Box Hill Hospital is joining the program as Princess Alexandra Hospital transitions into the Pivotal Trial.

The Regional Benefit Study is also progressing, supported by the Cooperative Research Centres Projects (CRC-P) Round 17 grant program. EMVision received the third A$0.4 million instalment from the grant in May 2026, with ethics approval for the study anticipated during the second half of CY2026.

The Regional Benefit Study is being conducted in Partnership with the Australian Stroke Alliance, Titan Pre-Hospital Innovation and South Australia’s Rural Support Service, reflecting the Company’s longer-term ambitions for regional and remote healthcare deployment.

Why the Announcement Matters

The addition of ischaemia detection alongside haemorrhage detection materially expands the potential clinical Utility of the emu™ Brain Scanner.

Ischaemic stroke represents approximately 80% of all stroke presentations, making it the largest segment of the stroke diagnosis pathway. Earlier bedside identification of ischaemic stroke could potentially accelerate treatment decisions involving thrombolysis or mechanical thrombectomy, where time-to-treatment remains critically important for patient outcomes.

From a commercial perspective, validating both haemorrhage and ischaemia capabilities within the same FDA pathway could significantly strengthen EMVision’s first-release product proposition. Rather than pursuing a narrower haemorrhage-only approval followed by a later indication expansion, the Company is attempting to consolidate multiple validation pathways into a single trial structure.

This strategy also appears Capital efficient. EMVision estimates that embedding ischaemia validation into the existing trial could save up to two years and avoid multi-million-dollar additional trial costs. For a clinical-stage medical technology company, reducing future funding requirements and compressing development timelines can be strategically significant.

The broader update also reinforces operational momentum across several workstreams simultaneously, including patient recruitment, additional site engagement, algorithm development studies and grant-supported regional healthcare initiatives.

Strategic Context

EMVision’s broader strategy centres on developing portable neurodiagnostic technology capable of assisting stroke triage in both hospital and pre-hospital environments.

The emu™ Brain Scanner represents the Company’s first-generation point-of-care device designed for in-hospital use, particularly within code stroke workflows. The second-generation “First Responder” device is intended for pre-hospital deployment in ambulances and emergency transport settings.

The current Pivotal (Validation) Trial is therefore the key regulatory gateway for the Company’s first commercial product in the United States.

By attempting to validate ischaemia detection alongside haemorrhage detection before initial FDA clearance, EMVision is seeking to enter the market with a broader clinical value proposition from launch rather than expanding functionality incrementally over multiple regulatory cycles.

The strategy is supported by the design of the existing trial structure, which allows additional diagnostic features to be sequentially validated without requiring entirely separate trials.

At the same time, the Continuous Innovation Study continues generating real-world scan data from stroke and traumatic brain injury patients, supporting ongoing algorithm refinement and feature development. The Regional Benefit Study extends this strategic positioning into regional and remote healthcare settings, where portable bedside imaging tools could potentially address infrastructure limitations and treatment delays.

Market Interpretation

A positive interpretation of the update would focus on the strategic logic of validating ischaemia detection within the same FDA pathway as haemorrhage detection.

Given that ischaemic stroke accounts for the majority of stroke presentations, the ability to support both detection pathways could materially expand the device’s addressable clinical use case and commercial attractiveness.

Investors may also view the recruitment progress, growing number of clinical sites, absence of device-related adverse events and ongoing grant support as indicators that operational execution remains on track.

At the same time, a more neutral interpretation would recognise that the announcement remains largely forward-looking. The additional endpoint has not yet been formally incorporated into the protocol, FDA discussions have not yet occurred, and final validation performance outcomes remain unknown until enrolment concludes and blinded data is analysed.

The timing of full enrolment — expected from late CY2026 or early CY2027 — also indicates that the pivotal read-out and FDA pathway remain medium-term milestones rather than near-term catalysts.

A more cautious interpretation may focus on the complexity of ischaemia detection itself. Detecting hyperacute ischaemic stroke is widely regarded as technically more challenging than haemorrhage detection, and the FDA may ultimately require additional data, revised thresholds or supplementary analysis before supporting expanded claims.

There also remains the possibility that haemorrhage and ischaemia endpoints progress on different regulatory timelines depending on final performance outcomes.

Risks and Missing Information

Clinical and Regulatory Risk remain central considerations for the EMVision program.

The Pivotal Trial’s primary objective requires haemorrhage detection sensitivity and specificity above 80%. Failure to achieve those thresholds would significantly affect the FDA De Novo pathway regardless of progress on ischaemia detection.

Importantly, the Company has not yet disclosed the proposed performance thresholds for the ischaemia endpoint, nor the final size of the required ischaemic patient cohort.

The FDA engagement process itself introduces another variable, as regulators may request additional data, design modifications or extended follow-up periods before supporting the expanded endpoint strategy.

Trial execution risk also remains relevant. Although EMVision described the required protocol changes as modest and incremental, adding a parallel endpoint could still affect recruitment pacing, statistical powering requirements and overall trial timelines.

Funding risk is another consideration. While EMVision held A$18.4 million in cash reserves as at 31 March 2026 and retains access to approximately A$6.2 million in additional non-dilutive grant funding, the Company has not outlined the timing of future funding requirements relative to FDA submission, commercialisation or Manufacturing scale-up.

Commercialisation risks also extend beyond regulatory clearance itself, including reimbursement strategy, pricing, distribution partnerships, manufacturing scalability and competitive response from incumbent neuroimaging technologies.

Investor Takeaway

This update represents a constructive operational and strategic development for EMVision Medical Devices Limited as it continues advancing the emu™ Brain Scanner toward FDA submission.

The proposed addition of an acute ischaemia detection endpoint has the potential to materially strengthen the device’s clinical relevance and commercial positioning if successfully validated within the current Pivotal Trial framework.

At the same time, the development remains largely forward-looking and subject to FDA alignment, successful protocol amendments and eventual clinical performance outcomes once enrolment and analysis are completed.

For investors, the key milestones from here include the FDA Q-Sub engagement outcome, formal protocol amendments, recruitment progress toward the 300-patient cohort target, future study read-outs, Regional Benefit Study ethics approval and any future funding developments tied to the broader commercialisation pathway.